Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 16/20 | 0.48 |
| ▸ | CASP9 | P55211 | 1/20 | 0.39 |
| ▸ | BIRC3 | Q13489 | 5/20 | 0.38 |
| ▸ | BIRC2 | Q13490 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117250 | 0.94 | XIAP (0.49) | XIAPCASP9BIRC3BIRC2CYP3A4 | |
| SCHEMBL2632208 | 0.94 | XIAP (0.49) | XIAPCASP9BIRC3BIRC2CYP3A4 | |
| SCHEMBL2113161 | 0.89 | XIAP (0.45) | XIAPCASP9BIRC3BIRC2CYP3A4 | |
| SCHEMBL2631846 | 0.89 | XIAP (0.45) | XIAPCASP9BIRC3BIRC2CYP3A4 | |
| SCHEMBL13048262 | 0.89 | XIAP (0.45) | XIAPCASP9BIRC3BIRC2CYP3A4 | |
| SCHEMBL23847519 | 0.89 | XIAP (0.45) | XIAPCASP9BIRC3BIRC2CYP3A4 | |
| SCHEMBL2632123 | 0.88 | XIAP (0.46) | XIAPCASP9BIRC3BIRC2CYP3A4 | |
| SCHEMBL2113168 | 0.88 | XIAP (0.46) | XIAPCASP9BIRC3BIRC2CYP3A4 | |
| SCHEMBL15095355 | 0.83 | XIAP (0.49) | XIAPCASP9BIRC3BIRC2CYP3A4 | |
| SCHEMBL2632188 | 0.83 | XIAP (0.40) | XIAPCASP9BIRC3BIRC2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130274278-A1 | IAP INHIBITORS | TETRALOGIC PHARM CORP (US) | 2013-10-17 | — | — | US | disclosed |
| US-8481495-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120094917-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010138496-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274278-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | XIAP 1/4885CASP9 63/4885BIRC3 5/4885 |
| US-20120094917-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | XIAP 1/4885CASP9 63/4885BIRC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.